论文部分内容阅读
Objective Colorectal cancer(CRC) is a heterogeneous disease in which both epigenetic alterations and gene mutations transform normal cells into cancer cells. Apart from a variety of standard treatments, there are few options available to improve a CRC patient’s overall survival(OS) and quality of a life. The objective of the present retrospective study was to analyze the response and toxicity associated with apatinib in patients with metastatic CRC(m CRC).Method Data on the use of apatinib as salvage therapy were collected from patients diagnosed with m CRC, Eastern Cooperative Oncology Group(ECOG) performance status ≤ 3, from the Luhe Hospital. A total of 17 patients with stage IV unresectable m CRC, who received at least one cycle of apatinib, between October 2015 and February 2017, were involved in this study. Our primary endpoints were the overall response rate(ORR) and disease control rate(DCR), and the secondary objectives were progression-free survival(PFS), OS and safety.Result Seventeen patients with a median age of 62 years(34–83 years) were enrolled. Twelve patients were male, and the location of the primary tumor was in the colon and the rectum in 9 and 8 patients, respectively. Liver metastasis was observed in 9 patients and lung metastasis in 5. The ECOG performance status was 0 to 2 in 13 patients. The ORR at the first evaluation was 17.6 %(3/17). The DCR was 82.4%(14/17). The median PFS was 3.0 months(95% confidence interval(CI): 1.924–4.076 months) and the median OS was 5.4 months(95% CI: 3.383–7.417 months). Grade 1–2 adverse events included hypertension(52.9%), fatigue(64.7%), anorexia(29.4%), hoarseness(23.5%), proteinuria(23.5%), and development of rashes(17.6%). Grade 3 adverse events included thrombocytopenia(5.9%) and proteinuria(5.9%). There were no Grade 4 adverse events in our analysis.Conclusions Apatinib was found to be both safe and effective in the treatment of advanced m CRC, and its associated toxicities were acceptable and manageable. However, further studies are required to validate these findings.
Objective Colorectal cancer (CRC) is a heterogeneous disease in which both epigenetic alterations and gene mutations transform normal cells into cancer cells. Apart from a variety of standard treatments, there are few options available to improve a CRC patient’s overall survival (OS) and quality of a life. The objective of the present retrospective study was to analyze the response and toxicity associated with apatinib in patients with metastatic CRC (m CRC). Method Data on the use of apatinib as salvage therapy were collected from patients diagnosed with m CRC, Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3, from the Luhe Hospital. A total of 17 patients with stage IV unresectable m CRC, who received at least one cycle of apatinib, between October 2015 and February 2017, were involved in this study Our primary endpoints were the overall response rate (ORR) and disease control rate (DCR), and the secondary objectives were progression-free survival (PFS), OS and safety. Resu lt Seventeen patients with a median age of 62 years (34-83 years) were enrolled. Twelve patients were male, and the location of the primary tumor was in the colon and the rectum in 9 and 8 patients, respectively. Liver metastasis was observed The ORF at the first evaluation was 17.6% (3/17). The DCR was 82.4% (14/17). The median PFS Grade 1-2 adverse events included hypertension (52.9%), fatigue (95% confidence interval CI: 1.924-4.076 months) and median medication was 5.4 months (95% CI: 3.383-7.417 months) (3.7%), 64.7%), anorexia (29.4%), hoarseness (23.5% no Grade 4 adverse events in our analysis. Confc Apatinib was found to be both safe and effective in the treatment of advanced m CRC, and its associated toxicities were acceptable and manageable. However, further studies are required to validate these findings.